Key result
Short-term intravenous heparin therapy did not prevent recurrent TIAs (16.2%) or cerebral infarction (6.8%) among high-risk patients with recent TIAs.
Why the study?
Does short-term intravenous heparin therapy prevent recurrent TIAs or cerebral infarction in patients with recent TIAs?
Observational (n=74)
Does short-term intravenous heparin therapy prevent recurrent TIAs or cerebral infarction in patients with recent TIAs?
Short-term intravenous heparin therapy did not prevent recurrent TIAs or cerebral infarction in high-risk patients with recent TIAs and was associated with bleeding complications.
Answers are grounded in this paper and cite their sources.
Short-term IV heparin lacks support for TIA prevention; leaves open efficacy in randomized trials.
We evaluated the efficacy of short-term intravenous heparin therapy in 74 patients with recent transient ischemic attacks (TIAs). The patients were treated after hospitalization until operation or long-term medical treatment was instituted. Heparin was given in a continuous infusion to maintain an activated partial thromboplastin time of 1 1/2 to 2 1/2 times control values. During the treatment period, 12 patients (16.2%) had recurrent TIAs and five (6.8%) had cerebral infarction. Bleeding complications occurred in nine patients (12.2%). In this limited series, heparin did not prevent recurrent TIAs or cerebral infarction among high-risk patients with recent TIAs.
No takes yet. Share an insight, caveat, or question.
Putman et al. (1985) conducted an observational in Recent transient ischemic attacks (TIAs) (n=74). Intravenous heparin was evaluated on Recurrent TIAs and cerebral infarction. Short-term intravenous heparin therapy did not prevent recurrent TIAs (16.2%) or cerebral infarction (6.8%) among high-risk patients with recent TIAs.
Synapse has enriched 10 related papers. Consider them for comparative context: